Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cellu Tissue Holdings, Inc. (CLU)
|
Add to portfolio |
|
|
|
| Price: |
$11.90
| | Metrics |
| OS: |
40.4
|
M
| |
-11
|
% ROE
|
| Market cap: |
$480
|
M
| |
6
|
% ROIC
|
|
Net debt:
|
$264
|
M
| |
3.9
|
x Debt/EBITDA
|
|
EV:
|
$745
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$68.6
|
M
| |
10.9
|
x EV/EBITDA
|
|
EBIT
|
$38.5
|
M
| |
19.4
|
x EV/EBIT
|
| EPS |
$19,999.64
| |
0.0
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Feb-28-10 | Feb-28-09 | Feb-29-08 | Feb-13-07 | Mar-01-06 | Feb-28-05 | Feb-29-04 | Feb-28-03 |
| Revenues | 511.3 | 519.0 | 443.1 | 247.4 | 96.7 | 332.9 | 290.3 | 232.4 |
| Revenue growth | -1.5% | 17.1% | | | -70.9% | 14.7% | 24.9% | |
| Cost of goods sold | 432.2 | 464.1 | 401.4 | 234.9 | 88.6 | 292.1 | 256.9 | 200.9 |
| Gross profit | 79.1 | 54.9 | 41.7 | 12.5 | 8.2 | 40.8 | 33.3 | 31.5 |
| Gross margin | 15.5% | 10.6% | 9.4% | 5.1% | 8.5% | 12.3% | 11.5% | 13.6% |
| Selling, general and administrative | 22.6 | 21.9 | 20.0 | 7.2 | 4.7 | 14.6 | 13.4 | 13.2 |
| EBITA | 56.5 | 33.0 | 19.6 | 0.9 | -3.3 | 22.0 | 19.9 | 18.4 |
| EBITA margin | 11.1% | 6.4% | 4.4% | 0.3% | -3.4% | 6.6% | 6.9% | 7.9% |
| Amortization of intangibles | 4.3 | 2.9 | | | | | | 0.1 |
| EBIT | 52.2 | 30.2 | 19.6 | 0.9 | -3.3 | 22.0 | 19.9 | 18.2 |
| EBIT margin | 10.2% | 5.8% | 4.4% | 0.3% | -3.4% | 6.6% | 6.9% | 7.8% |
| Pre-tax income | 11.3 | 5.9 | -0.2 | -10.8 | -8.3 | 3.0 | 12.3 | 26.7 |
| Income taxes | 7.5 | -0.6 | -3.9 | -4.2 | -1.9 | -0.1 | 5.2 | 11.0 |
| Tax rate | 66.7% | | 1882.6% | 38.6% | 22.7% | | 41.9% | 41.1% |
| Net income | 3.8 | 6.6 | 3.7 | -6.7 | -6.4 | 3.1 | 7.1 | 15.7 |
| Net margin | 0.7% | 1.3% | 0.8% | -2.7% | -6.7% | 0.9% | 2.5% | 6.8% |
| |
| Diluted EPS | $0.21 | $0.38 | $0.21 | | | | | |
| Shares outstanding (diluted) | 17.7 | 17.4 | 17.4 | | | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|